Phase I clinical trial of safety of L-serine for ALS patients

Todd D. LevinePhoenix Neurological Associates, Phoenix, Arizona,

Robert G. MillerForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,

Walter G. BradleyDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, and Correspondence[email protected]

Dan H. MooreForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,

David S. SapersteinPhoenix Neurological Associates, Phoenix, Arizona,

Lynne E. FlynnPhoenix Neurological Associates, Phoenix, Arizona,

Jonathan S. KatzForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,

Dallas A. ForshewForbes Norris MDA/ALS Research and Treatment Center, California Pacific Medical Center, San Francisco, California,

James S. MetcalfBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA

Sandra A. BanackBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA

Paul A. CoxBrain Chemistry Labs, Institute for Ethnomedicine, Jackson, Wyoming, USA

Your download is now in progress and you may close this window